PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
Pancreatic Enzyme Replacement Therapy (PERT) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
Sponsor: Digestive Care, Inc.
Terminated
Study was terminated due to difficulty in recruiting subjects.
Other terminated trials from Digestive Care, Inc.
- Exocrine Pancreatic Insufficiency · Phase NA · Sep 2010
- Chronic Pancreatitis · Phase PHASE4 · May 2010
More terminations from Digestive Care, Inc.
This PHASE1/PHASE2 trial investigates Pancreatic Cancer and Pancreatic Enzyme Abnormality and is currently terminated or withdrawn. Digestive Care, Inc. leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
-
Apr 2021 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
▶ Show 8 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2019 — Mar 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Digestive Care, Inc.
- Massimo Raimondo, M.D.
For direct contact, visit the study record on ClinicalTrials.gov .